Market closedNon-fractional
Alkermes/ALKS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Alkermes
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Ticker
ALKS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Dublin, Ireland
Employees
2,100
Website
www.alkermes.com
Alkermes Metrics
BasicAdvanced
$4.6B
Market cap
16.46
P/E ratio
$1.70
EPS
0.44
Beta
-
Dividend rate
Price and volume
Market cap
$4.6B
Beta
0.44
Financial strength
Current ratio
2.991
Quick ratio
2.417
Long term debt to equity
22.31
Total debt to equity
22.543
Interest coverage (TTM)
12.63%
Management effectiveness
Return on assets (TTM)
8.62%
Return on equity (TTM)
30.08%
Valuation
Price to earnings (TTM)
16.461
Price to revenue (TTM)
3.114
Price to book
3.62
Price to tangible book (TTM)
3.87
Price to free cash flow (TTM)
14.353
Growth
Revenue change (TTM)
3.14%
Earnings per share change (TTM)
179.95%
3-year revenue growth (CAGR)
11.08%
3-year earnings per share growth (CAGR)
62.37%
What the Analysts think about Alkermes
Analyst Ratings
Majority rating from 13 analysts.
Alkermes Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$350M
-7.18%
Net income
$37M
-67.35%
Profit margin
10.50%
-64.84%
Alkermes Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.55
$0.64
$0.22
$0.43
-
Expected
$0.46
$0.44
$0.51
$0.58
$0.70
Surprise
19.05%
44.70%
-57.15%
-26.26%
-
Alkermes News
AllArticlesVideos
Alkermes plc Reports Second Quarter 2024 Financial Results
PRNewsWire·3 days ago
Alkermes to Report Second Quarter Financial Results on July 24, 2024
PRNewsWire·1 week ago
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
PRNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alkermes stock?
Alkermes (ALKS) has a market cap of $4.6B as of July 27, 2024.
What is the P/E ratio for Alkermes stock?
The price to earnings (P/E) ratio for Alkermes (ALKS) stock is 16.46 as of July 27, 2024.
Does Alkermes stock pay dividends?
No, Alkermes (ALKS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Alkermes dividend payment date?
Alkermes (ALKS) stock does not pay dividends to its shareholders.
What is the beta indicator for Alkermes?
Alkermes (ALKS) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Alkermes stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.